The addition of tiragolumab (MTIG7192A) to atezolizumab (Tecentriq) and chemotherapy failed to enhance progression-free survival (PFS) and total survival (OS) in contrast with pembrolizumab (Keytruda) plus chemotherapy within the first-line remedy of sufferers with regionally superior, unresectable or metastatic nonsquamous non–small cell lung most cancers (NSCLC), lacking the first finish factors of the part 2/3 SKYSCRAPER-06 trial (NCT04619797).1
Within the intention-to-treat inhabitants, which consisted of sufferers handled in part 2 and three cohorts, the tiragolumab-based mixture led to decreased efficacy when it comes to PFS on the examine’s main evaluation (HR, 1.27; 95% CI, 1.02-1.57) and OS on the first interim evaluation (HR, 1.33; 95% CI, 1.02-1.73). Notably, OS information had been immature on the time of the evaluation.
Following the analyses, the examine shall be unblinded to sufferers and investigators, and Roche introduced that the corporate intends to cease the examine. Findings shall be shared with well being authorities and introduced at an upcoming medical assembly.
“These outcomes are disappointing because it was our hope that this mix would possibly yield improved outcomes for folks residing with metastatic nonsquamous lung most cancers,” Levi Garraway, MD, PhD, chief medical officer and head of International Product Improvement at Roche, acknowledged in a information launch. “We’re grateful to all the sufferers and healthcare professionals concerned within the examine, and we’ll leverage the learnings to tell our scientific understanding of the anti-TIGIT pathway and new avenues in most cancers analysis.”
Tiragolumab is an investigational novel immune checkpoint inhibitor that options an intact Fc area and is designed to selectively bind to TIGIT. The worldwide, randomized, placebo-controlled, double-blinded SKYSCRAPER-06 examine evaluated tiragolumab plus atezolizumab and chemotherapy vs pembrolizumab and chemotherapy as first-line remedy for 542 sufferers with nonsquamous NSCLC.
Sufferers had been required to be at the very least 18 years of age with histologically or cytologically documented regionally superior, unresectable or metastatic nonsquamous illness that was not eligible for healing surgical procedure and/or definitive chemoradiotherapy. Key inclusion standards included no prior systemic remedy for metastatic nonsquamous NSCLC; recognized tumor PD-L1 standing; measurable illness per RECIST 1.1 standards; a life expectancy of at the very least 12 weeks; and ample hematologic and end-organ perform.2
Sufferers had been excluded in the event that they harbored EGFR or ALK alterations; had a pulmonary lymphoepithelioma–like carcinoma subtype of NSCLC; had symptomatic, untreated, or actively progressing central nervous system metastases; had lively or a historical past of autoimmune illness or immune deficiency; or had a historical past of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or proof of lively pneumonitis.
Investigators randomly assigned sufferers in a 1:1 trend to obtain 600 mg of tiragolumab plus 1200 mg of atezolizumab and chemotherapy as soon as each 3 weeks; or placebo plus 200 mg of pembrolizumab and chemotherapy as soon as each 3 weeks. The chemotherapy routine in every arm consisted of 500 mg/m2 of pemetrexed plus 75 mg/m2 of cisplatin or carboplatin at space below the curve 5 as soon as each 3 weeks.
Investigator-assessed PFS and OS served because the trial’s main finish factors throughout phases 2 and three. Total response charge (ORR) was a main finish level throughout part 2. Key secondary finish factors included OS (part 2); impartial assessment facility–assessed PFS (part 3); investigator-assessed PFS primarily based on PD-L1 standing (part 3); OS primarily based on PD-L1 standing; investigator-assessed ORR (part 3); length of response (phases 2 and three); and security.
Relating to security, findings for the mix of tiragolumab plus atezolizumab and chemotherapy had been according to beforehand reported information. No new or sudden security findings had been reported.1
References
- Roche gives replace on part II/III SKYSCRAPER-06 examine in metastatic non-squamous non-small cell lung most cancers. Information launch. Roche. July 4, 2024. Accessed July 8, 2024. https://www.roche.com/media/releases/med-cor-2024-07-04
- A examine of tiragolumab together with atezolizumab plus pemetrexed and carboplatin/cisplatin versus pembrolizumab plus pemetrexed and carboplatin/cisplatin in contributors with beforehand untreated superior non-squamous non-small cell lung most cancers (SKYSCRAPER-06). ClinicalTrials.gov. Up to date June 21, 2024. Accessed July 8, 2024. https://www.clinicaltrials.gov/examine/NCT04619797
